Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

June 8, 2026 updated by: St. Jude Children's Research Hospital

This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.

Primary Objective:

To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.

Feasibility will be assessed by:

  • Participation Rate: Number of eligible survivors approached who enroll.
  • Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Hodgkin lymphoma survivors face elevated risks of cardiovascular disease and premature aging. HIIT, which alternates high-intensity effort with recovery periods, has shown benefits in adult cancer survivors but has not been tested in younger populations. This study will assess whether recently treated survivors can complete a remotely supervised 12-week HIIT program and evaluate its effects on multiple health outcomes. Participants will undergo baseline and post-intervention assessments including exercise testing, body composition, autonomic function, and blood biomarkers. The intervention is delivered via a secure web-based platform with live supervision by exercise physiologists.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Tennessee
      • Memphis, Tennessee, United States, 38105
        • Recruiting
        • St. Jude Children's Research Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
  • Participant is between the ages of >10 and <25 years old the time of enrollment.
  • Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
  • Participant has been medically cleared to participate in physical activity.
  • Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.

Exclusion Criteria:

  • Participant has evidence of relapsed disease.
  • Participant has a diagnosis of acute heart failure.
  • Participant reports currently participating in HIIT training or >420 minutes per week of moderate to vigorous physical activity.
  • Female participant who is currently pregnant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: HIIT Intervention Group
Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.
Behavioral: High Intensity Interval Training (HIIT)
Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Participation rate (percent of eligible participants approached who enroll)
Time Frame: Trial completion (12 weeks)
Descriptive statistics will be reported
Trial completion (12 weeks)
Completion rate (percentage of scheduled HIIT sessions attended and percentage of post-intervention testing sessions completed)
Time Frame: Trial completion (12 weeks)
Descriptive statistics will be reported
Trial completion (12 weeks)

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Cardiorespiratory fitness (VO2peak, ml/kg/min)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Ewing battery score of autonomic function (0 to 5 points)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Hand grip strength (kg)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Knee extension strength (N/kg)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Modified total neuropathy scale (0 to 24 points)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
DNA methylation
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Mitochondrial DNA copy number
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Telomere length (kb)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
High-sensitivity C-reactive protein (mg/L)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Interleukin-6 (pg/mL)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Physical activity (kilocalories per week)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Body mass index (weight and height will be combined to report body mass index in kg/m2)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Percent body fat (%)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Lean mass percentage (%)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks
Visceral fat level (score)
Time Frame: baseline at study entry, 12 weeks
Descriptive statistics of the change between baseline and 12 weeks will be reported
baseline at study entry, 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
St. Jude Children's Research Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Amy Berkman, MD, St. Jude Children's Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 8, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 27, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 27, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 29, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FITHOD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings